FibroBiologics adds retired NASA astronaut Kate Rubins to its board

FibroBiologics, Inc. (Nasdaq: FBLG), a clinical-stage biotechnology company based in Houston, has appointed Kathleen "Kate" Rubins, Ph.D., to its Board of Directors, according to a press release issued July 9, 2026.

Dr. Rubins, a microbiologist and genomics scientist, retired from NASA in 2025 after 16 years with the agency. She completed two spaceflights to the International Space Station, logging a total of 300 days in space. During her first mission, she became the first person to sequence DNA in space. She was elected to the National Academy of Medicine in 2025.

Dr. Rubins currently serves as the Founding Director of the Trivedi Institute for Space and Global Biomedicine at the University of Pittsburgh School of Medicine. She had previously been a member of FibroBiologics' Scientific Advisory Board since 2022.

Prior to joining NASA, Dr. Rubins was a Fellow and Principal Investigator at the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology, where she led research on the human immune response to infectious diseases. She holds a B.S. in Molecular Biology from the University of California, San Diego, and a Ph.D. in Cancer Biology from Stanford University Medical School.

Pete O'Heeron, Chief Executive Officer and Chairman of FibroBiologics, said, "Kate has been an invaluable member of our Scientific Advisory Board since 2022, and her firsthand understanding of how the human body adapts and heals in extreme environments makes her a natural fit for this expanded role."

FibroBiologics is focused on developing treatments for chronic diseases using fibroblast cells and fibroblast-derived materials, with more than 270 U.S. and international patents issued or pending.

You May Also Be Interested In

• FibroBiologics wins Australian patent for cannabidiol and cell therapy combo
• FibroBiologics Announces Australian Patent Accepted for Cannabidiol Adjuvant Therapy for the Treatment of Degenerative Disc Disease
• Sysco adds two directors, targets AI-driven cost savings of $100M